Drugs / LY03017
LY03017
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06980207 | May → Oct 2025 overdue | — | Luye Pharma Group Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06388551 | May 2024 → Mar 2025 | — | Luye Pharma Group Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY03017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06980207 ↗ |
| Known as | LPM526000133 | “Oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects.” NCT06980207 ↗ |
| Known as | LPM526000133 Fumarate | “Oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects.” NCT06980207 ↗ |
| Route | Oral | “single dose, administered orally” NCT06388551 ↗ |